An experimental COVID-19 vaccine could potentially provide protection against other corona viruses, including future COVID variants. Researchers say that a single dose of universal vaccine can cost less than a dollar. Virginia University professor and researcher Doctor Steven said, "The vaccine targets the portion of the spike protein that is common in nearly all corona viruses."
Preparation towards Universal Experimental Vaccine Manufacturing & nbsp;
Compared to the novel corona virus, other corona viruses cause about 25 percent of colds and a universal vaccine will prove to be the best medium for prevention. Buddhist doctor Amesh Adalaja of the John Hopkins Center for Health Security, Baltimore, points out that these results provide amazing opportunities to develop the universal virus vaccine of the corona virus. Another advantage of the new vaccine is the price. The experimental vaccine is based on genetically modified bacteria, the cost of large-scale preparations will be much lower than the current Kovid-19 vaccine.
Experimental COVID-19 can also provide protection from vaccine variants
For example, the current cost of mRNA Kovid-19 vaccine is $ 10 per dose, due to which developing countries will not be easy to use. A single dose of a bacteria-based vaccine for the prevention of cholera and fungi costs less than a dollar. Researchers say that the vaccine will target the spike protein, which is the invading part of human cells in all viruses. Now in all genome sequences of the novel corona virus, it was found that the spike protein portion of the corona virus caused by covid-19 did not show any change, and it is expected that this will not happen in the future.
If the new target proves to be effective in further research, then companies producing the Kovid-19 vaccine could potentially produce booster doses. The current vaccine forces human cells to produce incomplete parts of the covid spike protein, which the immune system responds to and creates a wall for future attack. Pfizer and Moderna’s vaccines provide genetic information to cells via messenger RNA, while Johnson & Johnson and AstraZeneca vaccines have used adenoviruses.
Both types of vaccine enter the cells and tells the cells to make vaccine antigen. In contrast, several strategies are being implemented for the preparation of experimental new vaccines. E-coli bacteria have been genetically prepared to remove the parts that make people sick, and instead the corona virus’s spike proteins have been placed on the bacteria’s surface to target. Researchers say the initial results are encouraging, but more work needs to be done on the experimental vaccine. The vaccine did not prevent infection, instead it protected the swine from developing severe symptoms.